Alflutinib methanesulfonate
Alflutinib methanesulfonate (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.Lung Cancer Phase 1 Clinical (In Vitro) :Alflutinib (Furmonertinib) mesylate is designed to inhibit EGFR active mutations as well as the T790M acquired resistant mutation.
Product Specifications
CAS Number
2130958-55-1
Product Name Alternative
AST2818 | AST-2818 | ASK120067
Purity
>98% (HPLC)
Solubility
DMSO : 5 mg/mL 7.52 mM
Smiles
CN (C) CCN (C) c1nc (OCC (F) (F) F) c (Nc2nccc (n2) c3cn (C) c4ccccc34) cc1NC (=O) C=C.CS (=O) (=O) O
Molecular Formula
C29H35F3N8O5S
Molecular Weight
664.705
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
N- (2- ((2- (dimethylamino) ethyl) (methyl) amino) -5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) -6- (2,2,2-trifluoroethoxy) pyridin-3-yl) acrylamide methanesulfonate
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
